Scribe Therapeutics priced an upsized initial public offering to raise roughly $129 million, extending a busy IPO pipeline for biotech and bringing the CRISPR developer to Nasdaq under ticker SCTX. The offering priced at $15 per share and began trading with a sharp jump on debut. The capital raise supports early clinical and IND-enabling work for in vivo gene editing programs, with Scribe highlighting a cardiometabolic focus led by STX-1150 (PCSK9 silencing) and additional preclinical assets targeting APOC3 and LPA. The IPO adds liquidity and attention to a space that has been increasingly competitive in non-rare genetic medicine.